Methods for treating cardiac valve disease
AssigneesThe Regents of the University of California, The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
InventorsChristina Theodoris, Deepak Srivastava
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating cardiac valve disease, e.g., calcific aortic valve disease (CAVD), by administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulae I-X or a pharmaceutically acceptable salt, solvate or prodrug thereof. Also provided are methods of identifying a candidate compound for treatment of cardiac valve disease, e.g., CAVD.
Claims4
A method of treating cardiac valve disease, the method comprising:
- administering to a subject in need thereof a therapeutically effective amount, in a range of about 30 mg/kg body weight to about 500 mg/kg body weight combined of XCT-790, (2E-3-(4-{[2,4-bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]acrylamide) and TG-003 (((Z)-1-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one)).
A method of treating cardiac valve disease by administering to a subject in need thereof a therapeutically effective amount of XCT-790 ((2E-3-(4-{[2,4-bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]acrylamide)) or TG-003 (((Z)-1-(3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one)).
Dependencies are inferred from the claim text.